Printer Friendly

PERSEPTIVE BIOSYSTEMS ANNOUNCES AWARD OF PATENT FOR PERFUSIVE CHROMATOGRAPHY PARTICLES

 CAMBRIDGE, Mass., July 22 /PRNewswire/ -- PerSeptive Biosystems, Inc. (NASDAQ: PBIO) announced today that the U.S. Patent and Trademark Office has issued to the company U.S. patent No. 5,228,989 for its flow- through particles that allow high-speed chromatography, a separation technology known as Perfusion Chromatography(R). The Perfusion Chromatography process is covered by U.S. patent No. 5,019,270, granted to PerSeptive Biosystems in 1991. The newly-issued patent covers the use, manufacture and sale of chromatography particles that permit high- speed, high-performance chromatography.
 PerSeptive's Chairman and CEO, Noubar B. Afeyan, Ph.D., stated: "This patent provides unequivocal coverage for POROS(R) media and extends coverage for the broader invention of Perfusion Chromatography. The claims of this new patent protect the essential structure of the particles themselves, thus preventing others from manufacturing and selling any high-speed chromatography media, which is, by definition, perfusive. We believe that numerous scientific publications on Perfusion Chromatography have demonstrated that the flow-through process of perfusion is the only mechanism for achieving high-speed, high- performance chromatography. This patent therefore confirms and strengthens PerSeptive's exclusive position in the field of high-speed chromatography."
 Prior to the invention of Perfusion Chromatography, all chromatographic materials involved a performance compromise among high capacity, high resolution and high speed, with high capacity and high resolution only achievable at very low speeds. The speed with which chromatographic separations can be performed with all non-perfusive media is limited by the slow rate of diffusion inside their pores. Perfusion Chromatography overcomes this limitation by using convection through the particles themselves to enhance the rate of transport inside their pores. The flow-through particles covered by PerSeptive's issued patents not only include POROS media, but other variations such as polymeric, inorganic (silica) or composite particles. The pores inside such particles may contain a thin film coating, or, for higher capacity, a thicker coating comprised of dense polymer chains referred to as gels, tentacles or fimbriae.
 PerSeptive Biosystems designs, manufactures and markets proprietary products and systems for the purification and analysis of biomolecules. These bioseparations products are designed to reduce significantly the time and cost required for the development and manufacture of biopharmaceuticals. The company's current and planned products for the purification and analysis of biomolecules are based on three interrelated core technologies: Perfusion Chromatography for high resolution separations of biomolecules 10 to 1,000 times faster than conventional chromatography, ImmunoDetection(tm) for real-time immunoassays in a flow-through cartridge format and Rational Surface Design(tm), synthetic surfaces that bind biomolecules with the high specificity of antibodies.
 -0- 7/22/93
 /CONTACT: Noubar B. Afeyan, president and CEO, or Robert A. Fein, senior vice president, finance, both of PerSeptive Biosystems, Inc., 617-621-1787/
 (PBIO)


CO: PerSeptive Biosystems, Inc. ST: Massachusetts IN: MTC SU:

DJ -- NE005 -- 4489 07/22/93 11:28 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 22, 1993
Words:465
Previous Article:KRAMER JOINS E.W. BLANCH CO. AS SENIOR VICE PRESIDENT
Next Article:NEW ENGLAND POWER COMPANY COMMITS TO WINDPOWER, OTHER RENEWABLE ENERGY
Topics:


Related Articles
PERSEPTIVE BIOSYSTEMS, INC.'S PROCESS DIVISION ANNOUNCES PILOT-SCALE SYSTEM MANUFACTURING AGREEMENT
PERSEPTIVE BIOSYSTEMS, INC. ANNOUNCES THE INTRODUCTION OF TWO NEW PERFUSION CHROMATOGRAPHY INSTRUMENTS
PHARMACIA BIOTECH ASKS COURT FOR NON-INFRINGEMENT RULING
PERSEPTIVE BIOSYSTEMS SUES PHARMACIA AND SEPRACOR FOR PATENT INFRINGEMENT
REGNIER, PH.D NAMED CHIEF TECHNICAL OFFICER OF PERSEPTIVE BIOSYSTEMS; CO-INVENTOR OF PERFUSION CHROMATOGRAPHY WILL LEAD TECHNOLOGY EFFORTS
PRETRIAL RULING MADE IN PERSEPTIVE BIOSYSTEMS' PATENT INFRINGEMENT CASE AGAINST PHARMACIA BIOTECH AND SEPRACOR
PERSEPTIVE BIOSYSTEMS COMPLETES EXCHANGE OFFER FOR UNITS OF PERSEPTIVE TECHNOLOGIES II CORPORATION
FURTHER PRETRIAL RULING MADE IN PERSEPTIVE BIOSYSTEMS' PATENT INFRINGEMENT CASE AGAINST PHARMACIA BIOTECH AND SEPRACOR
PERSEPTIVE BIOSYSTEMS, INC. COMPLETES TRANSACTION WITH CHEMGENICS PHARMACEUTICALS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters